COMMUNIQUÉS West-GlobeNewswire

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
13/08/2024
— Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024 — Preclinical data presented at the American Thoracic Society [...]
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
13/08/2024
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast [...]
Teknova Reports Second Quarter 2024 Financial Results
13/08/2024
Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-Tek SM Production and RUO+ manufacturing grade Company [...]
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
13/08/2024
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 [...]
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13/08/2024
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81. [...]
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
13/08/2024
Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products [...]
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
12/08/2024
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients [...]
Sanara MedTech Inc. Announces Second Quarter 2024 Results
12/08/2024
FORT WORTH, TX, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
12/08/2024
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors [...]
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
12/08/2024
Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5 [...]
Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock
12/08/2024
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of [...]
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
12/08/2024
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp [...]
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
12/08/2024
Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted [...]
Spectral AI Announces 2024 Second Quarter Financial Results
12/08/2024
Second Quarter Revenue Totals $7.5 Million Total Enrollment Exceeds 85% for Burn Center Pivotal U.S. Clinical Trial Q2 2024 Overview Research & Development Revenue of $7.5 Million Cash Position of $6.9 Million On [...]
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
12/08/2024
Company to host call at 4:30pm today NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel [...]
Stereotaxis Reports 2024 Second Quarter Financial Results
12/08/2024
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second [...]
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
12/08/2024
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial [...]
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX ® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with FDA [...]
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
Following FDA consultation, announced plans for validation of the Gen-2 Optejet ® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of [...]

Pages